Breaking
🇪🇺 EMA

Latest News

Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability Over mNEXSPIKE in Phase 4 Study
NewsApr 18, 2026

Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability Over mNEXSPIKE in Phase 4 Study

Sanofi's protein-based Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in first head-to-head phase 4 study presented at ESCMID.

Dr. Elena Rossi
Brand Institute Receives First EMA Approval for AI-Developed Pharmaceutical Brand Name Using Brandi Platform
NewsApr 18, 2026

Brand Institute Receives First EMA Approval for AI-Developed Pharmaceutical Brand Name Using Brandi Platform

Brand Institute achieves regulatory milestone as EMA approves first pharmaceutical brand name developed using AI-powered Brandi platform technology.

Prof. Marcus Webb
EMA Drug Patent Cliff 2026: Major European Pharmaceutical Exclusivities Set to Expire
NewsMultiple therapeutic areasApr 18, 2026

EMA Drug Patent Cliff 2026: Major European Pharmaceutical Exclusivities Set to Expire

Multiple high-cost EMA-approved drugs lose exclusivity in 2026, enabling generic competition and expanded patient access across Europe's healthcare systems.

Prof. Marcus Webb
EMA CHMP Recommends 6 New Medicines for Approval Including Treatments for Menopause, Liver Disease, and Rare Disorders
NewsApr 18, 2026

EMA CHMP Recommends 6 New Medicines for Approval Including Treatments for Menopause, Liver Disease, and Rare Disorders

European Medicines Agency's CHMP recommends 6 new medicines for marketing authorization, covering menopausal symptoms, liver disease, and rare genetic disorders.

Dr. Elena Rossi
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
NewsApr 18, 2026

EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026

EMA's CHMP recommends conditional approval for Adstiladrin gene therapy to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

Prof. Marcus Webb
EMA Approves Hanmi Pharmaceutical's HMPL-523 Herbal Medicine for Alzheimer's Disease Treatment
NewsApr 17, 2026

EMA Approves Hanmi Pharmaceutical's HMPL-523 Herbal Medicine for Alzheimer's Disease Treatment

European Medicines Agency grants marketing authorization for HMPL-523, marking first herbal medicine approval for mild to moderate Alzheimer's disease treatment.

Dr. Elena Rossi
Gene Therapy Market to Reach $43.8 Billion by 2034 as CRISPR and AAV Technologies Drive 12.27% Annual Growth
NewsApr 17, 2026

Gene Therapy Market to Reach $43.8 Billion by 2034 as CRISPR and AAV Technologies Drive 12.27% Annual Growth

Gene therapy market projected to grow 12.27% annually through 2034, driven by CRISPR and AAV advances, with North America leading at 56% market share.

Dr. Elena Rossi
Healthcare Cold Chain Logistics Market to Surge Through 2034 as Biopharmaceutical Demand Drives Asia-Pacific Growth
NewsApr 17, 2026

Healthcare Cold Chain Logistics Market to Surge Through 2034 as Biopharmaceutical Demand Drives Asia-Pacific Growth

Healthcare cold chain logistics market projected for significant growth 2026-2034, driven by rising biopharmaceutical demand and Asia-Pacific expansion.

Prof. Marcus Webb
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
NewsApr 17, 2026

AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status

AIM ImmunoTech plans Phase 3 trial for Ampligen in pancreatic cancer, backed by positive Phase 2 data and orphan drug designations in US and Europe.

Dr. Elena Rossi
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
NewsApr 17, 2026

AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study

AB Science obtains €25M clinical trial insurance for masitinib ALS Phase III study while implementing temporary European trial halt amid regulatory review.

Prof. Marcus Webb
MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
NewsOphthalmology - Inherited Retinal DiseasesApr 17, 2026

MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment

MeiraGTx acquired botaretigene sparoparvovec from J&J to treat X-linked retinitis pigmentosa, planning immediate global regulatory filings for approval.

Dr. Elena Rossi
Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM
NewsNon-small cell lung cancer (NSCLC)Apr 17, 2026

Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM

Beamion's zongertinib gains FDA accelerated approval for HER2-mutant NSCLC treatment following breakthrough therapy designation and NEJM publication.

Dr. Elena Rossi
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
NewsApr 17, 2026

TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies

TRI-611 molecular glue degrader gains FDA fast track status for ALK-positive NSCLC while Eisai's taletrectinib advances in Europe for ROS1+ lung cancer treatment.

Dr. Elena Rossi
Traws Pharma Advances Tivoxavir Marboxil to Human Influenza Challenge Trial, Reports Positive Ratutrelvir COVID Data
NewsApr 16, 2026

Traws Pharma Advances Tivoxavir Marboxil to Human Influenza Challenge Trial, Reports Positive Ratutrelvir COVID Data

Traws Pharma advances tivoxavir marboxil for once-monthly flu prevention and reports differentiated COVID treatment data for ratutrelvir versus Paxlovid.

Prof. Marcus Webb
TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications
NewsApr 16, 2026

TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications

TME Pharma announces Nature Communications publication of NOX-A12 triple therapy Phase 1/2 GLORIA trial results for brain cancer treatment.

Dr. Elena Rossi
New Additional Risk Minimization Measures (aRMMs) Training Course Launches to Enhance Pharmaceutical Patient Safety Protocols
NewsApr 16, 2026

New Additional Risk Minimization Measures (aRMMs) Training Course Launches to Enhance Pharmaceutical Patient Safety Protocols

PharSafer Associates launches comprehensive aRMMs training course focusing on regulatory frameworks and patient safety evaluation strategies for pharma professionals.

Prof. Marcus Webb
Healthcare Logistics Market to Surge $159.91 Billion by 2030, Driven by Biopharmaceutical Growth and Cold Chain Expansion
NewsApr 16, 2026

Healthcare Logistics Market to Surge $159.91 Billion by 2030, Driven by Biopharmaceutical Growth and Cold Chain Expansion

Global healthcare logistics market projected to grow $159.91 billion from 2025-2030 with 14.4% CAGR, driven by biopharmaceutical expansion and cold chain demands.

Prof. Marcus Webb
Medical Device Software Compliance Training Launches for EU MDR, IVDR and FDA Regulations in June 2026
NewsApr 16, 2026

Medical Device Software Compliance Training Launches for EU MDR, IVDR and FDA Regulations in June 2026

New online training course addresses critical medical device software compliance requirements under EU MDR, EU IVDR, and FDA regulations starting June 22-26, 2026.

Dr. Elena Rossi
ONWARD Medical Raises €40 Million in Capital Increase Led by EQT Life Sciences for Spinal Cord Stimulation Technology
NewsApr 16, 2026

ONWARD Medical Raises €40 Million in Capital Increase Led by EQT Life Sciences for Spinal Cord Stimulation Technology

ONWARD Medical secures €40M funding with €25M from EQT Life Sciences to advance spinal cord stimulation therapies for paralysis and movement disorders.

Prof. Marcus Webb
SAHPRA and African Medicines Agency Launch Continental Pharmaceutical Regulatory Harmonization Course for May 2026
NewsApr 16, 2026

SAHPRA and African Medicines Agency Launch Continental Pharmaceutical Regulatory Harmonization Course for May 2026

SAHPRA partners with African Medicines Agency for comprehensive regulatory affairs course covering continental harmonization and product registration.

Prof. Marcus Webb